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1. Introduction
The field of infectious diseases is an exciting field with new agents emerging continuously.
The emergence of new diseases is partly contributed by our growing population, expansion
of residential areas into previously uninhabited areas and increase in global travel. Most of
the emerging new infections are due to RNA viruses and nearly half have been described to
cause encephalitis or significant neurological symptoms [1].
This review will focus on encephalitis caused by enteroviruses. Encephalitis is basically in‐
flammation of the brain. Several viruses can result in encephalitis and some viruses, such as
Enterovirus 71 (EV71), have been documented to cause epidemics.
2. Virology of enterovirus
Enteroviruses are single-stranded, positive-sense RNA viruses belonging to the Picornaviri‐
dae family. They are associated with various human and animal diseases, and are tradition‐
ally classified into 4 groups, namely, Coxsackie A viruses, Coxsackie B viruses, echoviruses
and polioviruses, depending on the clinical presentation. Recently, however, enteroviruses
have been named numerically e.g. EV70 and EV71 in recognition of the similarities among
the 4 groups noted on genomic studies [2].
RNA viruses are known for their high spontaneous mutation rate, which is attributed to the
absence of proof reading in viral RNA polymerases. This invariably leads to the emergence
of new enteroviruses and consequently, new clinical presentations. Enterovirus 71 was first
described in California USA in 1969 [3] and will arguably be the next most important entero‐
virus after the eradication of poliovirus.
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The enterovirus is a small, non-enveloped spherical particle around 30nm in diameter. The
viral genomic RNA is encapsidated within the capsid shell comprising the VP1-4 capsid pro‐
teins. The capsid proteins are arranged into a symmetrical icosahedral lattice. These capsid
proteins recognize receptors on host cells and demonstrate antigenicity. The viral genome is
translated into a polyprotein around 250kDa which then undergoes cleavage via the viral
proteases. The viral non-structural proteins 2A-C and 3A-D are essential for the replication
of the virus within infected cells [4].
Phylogenetic studies of enterovirus 71 have identified 3 genotypes and numerous subtypes.
The 3 genotypes are A, B and C, whereas the subtypes are classified numerically. Increased
neurovirulence have been attributed to certain subtypes, such as genotype C1 [5]. Still, the
exact pathogenesis for the variation in disease presentation is unknown.
3. Epidemiology
Herpes simplex virus holds the dubious honor of being the commonest cause of acute focal
encephalitis, and is thus the presumptive diagnosis in patients with viral encephalitis. How‐
ever, prospective studies have shown that about 9% have a different etiology and may be
due to enteroviruses [6, 7]. Enteroviruses have a worldwide distribution, but recent out‐
breaks of EV71 have been centered in Asia, particularly East and Southeast Asia [8-16]. En‐
terovirus 71 is not the only enterovirus that involves the central nervous system (CNS). In a
Canadian survey of enteroviral infections of the CNS from 1973 to 1981, coxsackie-virus A9,
B1, B2, B3 and B5, echoviruses type 6, 7, 9, 11, 30, poliovirus type 2 were isolated as well
[17]. The incidence of encephalitis specifically in enterovirus infections is reported to be at
3% [18], with the majority presenting meningitis.
Clinically evident infection occurs mainly in children with few cases reported in adults [19].
There is a male preponderance [19]. In children, the infection usually presents as hand, foot
and mouth disease (HFMD). Yet from the late 1990s onwards, increasingly severe cases
caused by enterovirus have been documented, particularly involving EV71. In adults, there
have been a few case reports occurring after immunosuppressive therapy such as rituximab
[20]. Rituximab is a chimeric anti-CD20 monoclonal antibody that can cause profound B-cell
lymphopenia and antibody deficiency. There are 3 main different clinical neurological com‐
plications of EV71 infection; 1.flaccid paralysis and encephalitis [3, 21], 2.HFMD and menin‐
goencephalitis [22-24] and 3.HFMD or herpangina and rhombencephalitis with neurogenic
pulmonary edema [16, 25-27].
The incidence of CNS complications in enterovirus infection has been reported to range
from 2-10% [28]. Even so, according to a prospective study of 773 children [5] and retrospec‐
tive study of 423 patients [19], it can go as high as to 19-42%, respectively. Of the 773 chil‐
dren, EV71 was isolated in 277 (41%) and out of the 277 children, a further 28 had
coinfections with a second virus (other enteroviruses, adenovirus and unidentified virus)
[5]. Coxsackie A virus was isolated in 85 patients and out of these, 4 had coinfections as
well. Other enteroviruses, adenoviruses or unidentified viruses were isolated in 58 [5].
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While coinfections with other enteroviruses did not appear to increase the risk of neurologi‐
cal complications, an association was found between patients who were coinfected with
dengue viruses and neurological symptoms [5]. Similarly, in the retrospective study of 423
patients, those with CNS involvement were more likely to have EV71 (21%) instead of cox‐
sackie A virus infection (16%). In addition, rate of disease progression and severity was re‐
ported to be greater in EV71 infection [19].
4. Pathogenesis
The reservoir of human pathogenic enterovirus is humans and transmission of enteroviruses
occurs through the fecal-oral route via droplets or in utero [28]. Infection starts in the gastro‐
intestinal system with proliferation in the pharynx or intestinal lymph nodes before dissemi‐
nating to the rest of the body.
In vitro studies of EV71 show that the virus binds to DLD-1 intestinal cells which express
sialic acid (SA) linked glycan on the cell surface [29]. Decreasing O-linked glycans or gly‐
colipids  on  the  cell  surface  decreased  EV71  infection  of  DLD-1  intestinal  cells  but  this
was  not  reproducible  on  decreasing  N-linked  glycans.  SA linked  glycans  isolated  from
human milk also inhibited EV71 infection of DLD-1 intestinal cells [29], suggesting poten‐
tial therapeutic use.
The first step for a virus to infect the CNS is to cross the blood brain barrier (BBB). The BBB
serves as a physical barrier, consisting of endothelial cells joined to each other by tight junc‐
tions and surrounded by foot processes of astrocytes, preventing access to the CNS. The me‐
ninges, choroid plexus and ependymal cells lining the ventricles also prevent access. Within
the CNS are also dendritic cells and macrophages that detect pathogens and contribute to
the host defense response. In utero, the BBB has not fully matured and viruses crossing into
the placental circulation can also result in CNS infection.
Several RNA viruses causing neurological symptoms e.g. poliovirus, enter the CNS through
axonal transport from the peripheral nervous system (PNS), circumventing the blood brain
barrier. Coxsackie-virus B3 on the other hand targets nestin+ myeloid cells which subse‐
quently migrate through ependymal cell layer of the BBB into the CNS [30]. Other enterovi‐
ruses such as EV71 cross the BBB by binding to receptors e.g. P-selectin glycoprotein
ligand-1, infecting cells (leucocytes and lymphocytes) that normally cross the BBB [31],
hitchhiking their way into the CNS. Enterovirus 71 and coxsackie-viruses have also been
shown to bind to scavenger receptor class B member 2 (SCARB2) found on fibroblasts and
GPI-anchored protein decay-accelerating factor found on epithelial cells in the CNS, gaining
entry into the CNS [28, 32]. SCARB2 participates in membrane transportation and the re-or‐
ganization of endosomal and lysosomal compartments [33]. The coxsackievirus and adeno‐
virus receptor (CAR) also facilitates viral entry in a caveolin-dependent or independent
manner [32, 34] while human poliovirus receptor, an adhesion molecule, is used by human
poliovirus in a caveolin independent manner but dynamin-dependent manner to gain entry
[32, 35]. The receptors and varying method of entry in different cell types may explain for
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the tropism to a certain degree. Human poliovirus receptors are found in high levels in the
anterior horn cells of the spinal cord, accounting for the predilection of poliovirus for infec‐
tion anterior horn cells [36]. However, there are other factors that contribute to the tropism
of the viruses such as cell proliferation. It has been reported that coxsackievirus 3B targets
neural progenitor and stem cells and viral replication increases markedly during cell divi‐
sion and when the cells are arrested at the G1 or G1/S phase while viral replication is reduced
in quiescent cells in the G0/G2/M phase [37].
The human immune system consists of adaptive and innate immunity, both of which uti‐
lizes pattern recognition receptors (PRR) e.g. Toll-like receptor and RIG-I-like receptors that
detect viral nucleic acids and initiate host defence [38], including modulating the release of
chemokines, cytokines and interferons [39]. An appropriate host response to viral infection
requires a complex interplay between the innate and adaptive immune system.
After entry into the CNS, glial cells which constitute part of the CNS innate immune system,
detect the intracellular viral nucleic acid, and stimulate the release of IFN-1, causing apopto‐
sis and inhibit viral replication. It is, however, important to note that collateral damage in‐
curred upon activation of cytolytic T cells during an adaptive immune response within the
CNS may be more damaging to neurons than the infection. Furthermore, both greater cyto‐
kine induced tissue destruction due to higher systemic levels of proinflammatory cytokines
like IL-6, IL-1β, and TNF [40] and the pervasive infiltration of leukocytes into the CNS exac‐
erbate the neuropathology linked to enteroviruses [41]. Due to this, the host may contain im‐
mune response towards viral infection within the CNS.
Even so, viruses have also evolved to escape host defence by producing viral proteins that
inhibit host anti-viral response. For example, EV71 produces protein 3C which inhibits RIG-I
like receptors and thus blocks host IFN-1, and protein 2C which inhibits IkB kinase beta
phosphorylation, consequently blocking the TNF alpha activated NκB signaling pathway
[42, 43]. In vitro studies also showed that protein 2C stimulates neuronal apoptosis via acti‐
vation of the Abl-Cdk5 pathway [44]. Interestingly, in vitro studies of coxsackievirus A16
which is less neurovirulent than EV71 [45] may suggest that coxsackievirus A16 stimulates
Abl to a smaller degree and does not stimulate Cdk5 [44]. Viruses can also dodge the adap‐
tive immune system by binding to dendritic cell specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN). The DC-SIGN is a receptor present on macrophages and
dendritic cells which recognizes and binds to pathogen associated molecular patterns
(PAMPs) on viruses, bacteria and fungi. The binding itself stimulates phagocytosis and re‐
sults in pathogen entry into dendritic cells and T-cells. Intracellular entry is not only mediat‐
ed via DC-SIGN but also by other receptors such as CD36 and CD163. This results in
suboptimal T and NK cell response as viral proteins inhibit IFN-1 synthesis and escape im‐
mune surveillance.
Neurological complications are reported at higher frequencies in younger children. The ex‐
act pathogenesis remains unknown, but research has elucidated a number of differences be‐
tween patients who developed such complications and those who do not.
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In a case-control study of 78 children who had EV71 infection, of which 31 children devel‐
oped meningoencephalitis, expression of CD40-ligand on T cells was significantly lower in
cases than in controls in the acute phase, but not in the convalescent phase of the disease
[46]. CD40 ligand expression on T cells is recognized as a marker of T and B cell interaction
[47]. Thus, a decrease in expression may suggest a decrease in stimulation of B cells, anti‐
body class switching and antibody production. Yet, there was no significant difference in
lymphocyte proliferation between cases and controls. In cases with meningoencephalitis, it
was also noted that interleukin 4 production was significantly lower in cases than in con‐
trols during the acute phase, suggesting a decrease response from Th2 cells which stimulate
the humoral immune system [46]. This suggests that a compromised immune status precipi‐
tates the fulminant progression of EV infections.
In the same study, significant polymorphism of the cytotoxic T lymphocyte antigen-4
(CTLA-4) was noted, with cases having more G/G genotype at position 49 of exon 1 than in
controls. CTLA-4 is involved in T cell anergy and apoptosis, and different polymorphisms
has been linked to infectious and autoimmune conditions [46].
In enterovirus infection, autophagocytosis is subverted and induced in infected neurons, al‐
lowing for intracellular replication of viral particles before host cell death occurs. Autopha‐
gy is usually a protective process that occurs in cells to sequester and breakdown unwanted
organelles or protein aggregates. In poliovirus [48] and coxsackievirus B4 [49] infections,
however, it has been induced to assist in virus replication instead. It is postulated that enter‐
ovirus utilizes the autophagosome membrane for viral replication and increase in viral repli‐
cation is associated with autophagy induction [49]. The exact mechanism by which
autophagocytosis increases viral replication is currently unclear.
Non-structural 3C protein of EV71 has been reported to block polyadenylation of host mes‐
senger RNA while non-structural 2A protein impedes the host cap-dependent translation
and simultaneously stabilizes polysomes enhancing translation of viral messenger RNA
[50]. Non-structural 2A protein thus boosts viral protein synthesis, and it has been shown to
be necessary for host cell apoptosis as well [51]. Accordingly, it is assumed that by deactivat‐
ing the host cell translation, enteroviruses may directly cause apoptotic cell death in neu‐
rons. Enteroviruses bring about both anti-apoptotic (non-structural 3A and 2B proteins) and
pro-apoptotic effects (VP2, non-structural 2A and 3C proteins) on the host cell [52]. Viral
non-structural protein 2B is also known to be a viroporin that increases permeability of host
cell resulting in eventual cell death.
The highest  rates of  infections occur in young children below 4 years of  age,  with fatal
infections most commonly occurring at the ages of 6-11 months [13, 16, 53]. This age pe‐
riod is also associated with a decline in maternal antibodies within the child. Enterovirus
71 infects human peripheral blood monocytes, and it is postulated that in the presence of
sub-neutralizing amounts of anti-EV71 antibodies, infectivity is enhanced [54]. This is al‐
so known as antibody-dependent enhancement (ADE), widely described in dengue infec‐
tion  as  well  as  other  viral  infections  such  as  human  immunodeficiency  virus  infection
[55]. Heterotypic non-neutralizing antibodies bind to the virions, forming EV71-antiEV71
antibody complexes,  which subsequently  bind to  Fc-R on human monocytes  and there‐
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fore, enhancing infectivity. In vitro experiments have shown that the addition of immune
sera from patients increased EV71 infection of THP-1 cells, a leukemia cell line of macro‐
phage lineage with monocytic markers, whereas addition of Fc-RI (CD64) significantly in‐
hibited the infection [54].
Furthermore, patients who suffer from neurogenic pulmonary edema have been reported to
have lower absolute monocyte counts, CD4, CD8 and NK cells counts as compared to pa‐
tients who had autonomic nerve system abnormalities and uncomplicated brainstem ence‐
phalitis [56].
5. Pathogenesis of neurogenic pulmonary edema
Patients with enterovirus encephalitis who suffer from pulmonary edema, pulmonary hem‐
orrhage and cardiopulmonary collapse usually have fairly normal premorbid cardiac func‐
tion with normal pulmonary artery pressures and vascular resistance [56]. Myocarditis is
also not evident on autopsy reports [57].
Involvement of  the medulla and hence,  the vagal  nucleus and medial  reticular nuclei  is
postulated  to  cause  pulmonary  edema  [58,  59].  Neurogenic  pulmonary  edema  occurs
when there is  pulmonary edema and CNS disease in the absence of  underlying cardio‐
pulmonary disease [58].  While the pathogenesis is  not clear,  it  is  believed that an insult
to the medulla results in torrential release of catecholamine. This in turn, causes a rapid
increase  in  total  peripheral  vasoconstriction  and  systemic  hypertension,  shifting  blood
from the systemic circulation to the pulmonary circulation. Since the pulmonary circula‐
tion is usually a low resistance system, it is unable to adapt to the sudden increase in hy‐
drostatic  pressure.  The  results  are  protein  rich  pulmonary  edema  and  pulmonary
hemorrhages.  The  resulting  ‘‘catecholamine  storm’’  induces  catecholamine  cardiotoxicity
as  well  including  coagulative  myocytolysis,  myofibrillar  degeneration,  and  cardiomyo‐
cytes apoptosis [60]. This neurogenic nature is validated by MRI findings of brainstem in‐
volvement  [61]  and  postmortem  examinations  of  mortality  cases  of  enterovirus
encephalitis  in  which  pathological  lesions  were  predominantly  located in  the  brainstem
and the spinal cord, rather than in the lung or heart [21, 27, 62].
6. Pathogenesis in chronic infection
Chronic infection by enterovirus has been reported [63] and it is postulated that the persis‐
tence of infection alters normal neural stem cell migration and or differentiation. Although
viral latency has yet to be established, there is evidence for their persistence in infected cells
for years [64-66]. Therefore, enteroviral RNA may be reactivated upon stimulation. In the
case of hypogammaglobulinaemia, reactivated enterovirus is not inactivated and can spread
freely. In the same degree, persistent meningoencephalitis has been reported in patients
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with agammaglobulinemia [67, 68]. In fact, the first case of enteroviral meningoencephalitis
was reported in a patient with agammaglobulinemia [69].
7. Clinical signs and symptoms
Enteroviruses can cause a wide spectrum of clinical diseases, including but not limited to
the common cold, gastroenteritis, hand, foot and mouth disease (HFMD), herpangina, myo‐
carditis, severe neonatal sepsis-like disease, hepatoadrenal failure, aseptic meningitis, acute
flaccid paralysis, meningoencephalitis, encephalitis, neurogenic pulmonary edema, pulmo‐
nary hemorrhage and shock induced sudden death especially in the young age group [13,
62, 70]. The neurological presentations include aseptic meningitis, benign intracranial hyper‐
tension, acute flaccid paralysis, opsoclonus-myoclonus syndrome, Guillain-Barre syndrome,
transverse myelitis, encephalitis, cerebellitis, brainstem encephalitis, rhombencephalitis and
encephalomyelitis [13, 25, 26, 71-76].
Clinical manifestations can be classified according to 5 grades. In grade I, patients demon‐
strate clinical signs of HFMD and/or herpangina with erythematous vesicles on palms, soles,
elbows and trunk and oral ulcers on mucosa of lips as well as palate. The majority of pa‐
tients will display grade I symptoms as seen in the 1998 Taiwan epidemic where 5506 out of
5632 patients were classified to have grade I symptoms [61]. In grade II, patients suffer from
fever, photophobia, vomiting, headache, and abdominal pain. Patients who initially exhibit
grade II symptoms may subsequently progress onto grade III. The disease may take a fulmi‐
nant course in patients younger than 2 years of age, deteriorating directly to grade IV in a
short period of time. In grade III, patients may demonstrate lethargy, apathy, drowsiness,
tachycardia, cranial nerve involvement (VI-XII), myoclonic jerks, monoparesis or hemipare‐
sis, conjugate gaze disturbances, dyspnea and ataxia. Patients with grade III symptoms that
are younger than 2 years of age usually progress to grade IV while older patients tend to
recover completely after 1-2 weeks. In grade IV, patients experience hypothermia, pulmona‐
ry edema, respiratory failure, neurogenic shock and semicoma. In the last stage, grade V,
there is pulmonary hemorrhage, respiratory distress syndrome, cardiorespiratory failure,
coma and death. According to symptomatology, encephalitis is suspected in grade III-IV.
HFMD and herpangina are generally mild, self-limiting illnesses that occur in infants and
young children. The culprit virus for HFMD and herpangina is usually coxsackie-virus A16 or
EV71 [8, 14, 19]. Despite this, a small percentage of patients can rapidly decompensate and die
within days. In cases where neurological complications occur, the culprit viruses isolated are
usually EV71 and coxsackie-virus A16 [19] in some instances other echovirus 7 [77, 78].
Patients who had CNS complications were usually younger and more likely to have symp‐
toms of fever, vomiting, breathlessness and signs of shock that includes cold peripheries and
poor urinary output [5]. The exact symptoms and signs depend on the extent of CNS in‐
volvement. For example, in EV71 encephalitis, clinical signs of lethargy and cranial nerve
palsies such as conjugate gaze disturbance, dyspnea and tachycardia suggest involvement of
the brain stem, [61] and this is further substantiated by the magnetic resonance imaging.
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8. Investigations and diagnosis
In general, profound leucopenia is usually noted in patients with severe EV71 infections
[56]. This is attributed to T-cell apoptosis as EV71 infection may increase FasL expression.
• Investigations: Lumbar puncture
A common investigation in the presence of neurological symptoms would be a lumbar
puncture. In aseptic meningitis, there is usually lymphocytic cerebrospinal fluid (CSF) pleo‐
cytosis [20] and normal glucose levels [79]. Yet in some of the patients, neutrophilia was ob‐
served with low glucose levels less than half of that of plasma glucose instead [5].
• Investigations: Magnetic resonance imaging
Magnetic resonance imaging of the brain is also a useful investigation. Reports of magnetic
resonance imaging of polioencephalitis are rare as poliovirus is currently rarely seen in de‐
veloped countries. The few imaging reports of polioencephalitis reveal involvement of the
midbrain and posterior medulla and pons [61].
During the 1998 Taiwan EV71 epidemic, magnetic resonance features were described by
Shen et al [61]. Out of 15 patients classified in grade III with clinical encephalitis, 10 had ab‐
normal magnetic resonance imaging scans. Of the patients with abnormal scans, all 10 dem‐
onstrated hyperintense lesions of the posterior medulla and pons on T2 weighted images
but not on T1 weighted images, which implies acute inflammation. The majority showed in‐
volvement of the mesencephalon and dentate nuclei of cerebellum, and in severe cases, the
ventral horns of the spinal cord and deep supratentorial nuclei as well [61]. The inclusion of
the brainstem is supported by pathological findings on autopsy [26, 80], with inflammation
limited to the gray matter of the spinal cord and medulla as well as the tegmentum of the
midbrain and pons [80]. It is of note that EV71 and poliovirus affect the same areas of the
brain and the areas of involvement demonstrated on the nuclei correlated with the clinical
symptoms and signs. A marked difference would be that although the inflammation of infe‐
rior olives is reported in EV71 infection, it is absent in bulbar poliomyelitis [80].
Newer techniques in magnetic resonance imaging such as fluid attenuated inversion recov‐
ery and diffusion weighted imaging allow detection of subtle meningeal and cortical abnor‐
malities that can occur in meningoencephalitis [81]. Consequently, in patients stable enough
to undergo scans, magnetic resonance imaging can reveal areas of CNS involvement. This
allows greater diagnostic accuracy and perhaps predicts the need for cardiothoracic support
before patients deteriorate too rapidly.
9. Diagnostic methods
Diagnosis normally depends on (a) rise in virus specific acute and convalescent antibody tit‐
ers, (b) isolation of the virus via viral cultures from throat swabs, stool specimens and CSF
samples (c) visual identification of virus via (i) electron microscopy (ii) unique histological
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features and/or (iii) histochemical staining, (d) in situ hybridization assays or (e) polymerase
chain reaction (PCR) to amplify viral nucleic acids [82, 83]. Since some enteroviruses such as
coxsackievirus A [84] do not grow in standard cell cultures [85], the extensive use of PCR
with its generally high specificity and sensitivity has greatly improved diagnosis for numer‐
ous pathogens. The overall sensitivity, specificity, positive and negative predictive values
have been reported to be 85.7%, 93.9%, 61.7% and 98.3%,respectively, using viral culture as
the gold standard [86]. However, the majority of clinically suspected viral encephalitis are
still of unknown etiology. It is presumed as well that enterovirus will be detectable in the
gastrointestinal (GI) tract, but in the case of chronic encephalitis, by the time the disease sur‐
faces, the virus may have cleared from the GI tract and be undetectable in the stool. Addi‐
tionally, due to low viral concentration, detection of viral RNA in the CSF early after
manifestation may be challenging as well.
In EV71 encephalomyelitis, inflammation is stereotypical. Common areas of involvement
are the spinal cord, brainstem, hypothalamus, cerebellar dentate nucleus, cerebral cortex
and meninges. The anterior pons, corpus striatum, temporal lobe, hippocampus and cerebel‐
lar cortex are spared. These areas of involvement facilitate the differentiation of encephalitis
due to EV71 from Japanese encephalitis virus [87]. The nature of the lesions, however, is
non-specific, with inflammatory infiltration of perivascular and parenchymal tissue, edema,
necrosis, stimulation of microglial cells and phagocytic destruction of neurons[83].
The tests currently available have a low diagnostic yield, even in the case of PCR which has
high specificity and high sensitivity. This is shown in a meta-analysis conducted in 2010
which reviewed 41 studies on the etiology of encephalitis [88]. In 26 of the studies, more
than 50% of the cases were of unknown etiology [88]. Identifying the viral etiological agent
enables effective preventive measures and treatments to be implemented.
The European Union Concerted Action on Virus Meningitis and Encephalitis conducted a
multicenter retrospective study to evaluate the Amplicor Enterovirus PCR test [86]. 476 CSF
samples were collected from 9 laboratories in 5 European countries and analysed via cul‐
tures and PCR [86]. Out of 476 samples, 50 were positive via cultures and 66 via PCR. Rela‐
tive increase in rate of positivity via PCR in relation to culture is thus 32%. Among the 50
samples positive by cultures, 38 were positive while 12 were negative by PCR. On repeat
testing of the 12 samples that were culture positive but PCR negative with a different set of
primers and probes, 4 of the samples became PCR positive [86]. On the other hand, in the 66
samples positive via PCR, 28 were negative via cultures [86]. Interestingly, in samples from
patients with meningitis following the case definition of CSF pleocytosis (more than 10 leu‐
kocytes/mm3), 25 were positive via cultures and 45 via PCR, thus there were samples from
patients who did not satisfy the criteria for pleocytosis and yet had enterovirus infection.
The California Encephalitis Project (CEP) conducted from 1998-2000 evaluated samples from
334 patients with case definition of encephalitis, which is encephalopathy requiring hospi‐
talization plus one of the following: fever, seizure, focal neurologic findings, cerebrospinal
fluid pleocytosis and electroencephalographic or neuroimaging findings consistent with en‐
cephalitis [89]. Encephalopathy is defined as depressed or altered level of consciousness
lasting 24 hours, lethargy and/or change in personality [89]. 9% of the cases had a confirmed
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viral agent, 3% a confirmed bacterial agent, 1% a confirmed parasitic agent, 10% a non-infec‐
tious etiology and 12% a possible etiology identified. 3% had a non-encephalitis infection
identified. Nevertheless, CEP is not population based and the study group consisted of diag‐
nostically challenging cases. Therefore, the rate of unknown etiology cases may be an over‐
estimate when extrapolated to the general population.
Diagnostic strategies that have emerged recently include MassTagPCR, panmicrobial DNA
microarrays and high-throughput DNA pyrosequencing [82]. MassTag PCR is a multiplex
PCR assay utilizing primer pairs targeting highly conserved gene sequences that represent a
wide variety of potential pathogens. The primer pairs have been tagged with MassCodes
that are used to identify the etiological agent. There are different MassTag PCR systems
with different primers for different clinical specimens and presentations. Clinical use of this
method has demonstrated effectiveness in identification of pathogens [90-93]. Panmicrobial
DNA microarrays utilize a single chip with numerous highly conserved gene sequences,
permitting the swift identification of pathogens similar to that of MassTag PCR [94, 95].
Clinical use of this diagnostic method has also demonstrated efficacy in pathogen identifica‐
tion [96-98].
High-throughput DNA pyrosequencing on the other hand, does not make use of highly con‐
served gene sequences. Instead, it uses random primers to amplify all RNA after removing
human chromosomal DNA from the sample [99]. Amplification products are then se‐
quenced via pyrosequencing wherein DNA polymerases synthesize complementary strands
to the amplified products and each enzymatic attachment of a complementary nucleotide re‐
sults in an emission of a light signal. The light signal is recorded and the sequences are iden‐
tified and subsequently analyzed to look for pathogens. This technique allows for
identification of novel pathogens [100].
10. Treatment
At present, only herpes simplex encephalitis, one of the more prevalent infective encephali‐
tis, has a specific treatment validated by scientific research. It is treated with aciclovir [101].
Effective treatment is lacking for other viruses and mainly symptomatic in nature.
Currently, intravenous immunoglobulin (IVIG) is administered to patients with severe
HFMD [5]. Enteroviruses are cleared from the host by antibody-mediated mechanisms (22),
and IVIG is an effective treatment option. Various routes of administration have been docu‐
mented including intravenous, intrathecal and intraventricular with different degrees of
success [102-104].
11. Potential treatments in the future – vaccines
However, the best defence would be prevention through vaccination, especially in the case
of rabies, polio, mumps and measles. Vaccination may be an option to prevent infection by
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enteroviruses as well, but the potential ADE phenomenon is an important consideration in
the development of a safe and effective vaccine. The genetic diversity of enterovirus strains
therefore complicates the development of vaccines [105].
12. Potential treatments in the future – anti-virals
Ribavirin, a broad-spectrum antiviral synthesized by ICN pharmaceuticals, Inc., USA inhib‐
its the replication of a variety of enteroviruses. Studies on EV71-infected mice has shown
that ribavirin can reduce mortality by reducing the viral loads in tissues. The required dos‐
age of ribavirin is close to the initial dose of the drug administered intravenously to treat
patients with encephalitis caused by Nipah virus [106]. Given these results, ribavirin may
be, in combination with interferon, deployed to combat potentially fatal EV71 infection. In‐
terferon has a synergist effect and this combination is already adopted as a standard therapy
for HCV-infected patients [107].
Pyridyl imidazolidinone is a novel class of EV71 inhibitor [108]. It was first identified using
computer-assisted drug design. It targets EV71 capsid protein VP1 and time course experi‐
ments on one of the pyridyl imidazolidinones, BPR0Z-194, have shown that viral replication
is effectively inhibited in early stages, suggesting that the compound inhibits adsorption of
virions and/or viral RNA uncoating [108]. Resistant strains do exist, and sequence analysis
has demonstrated that a single amino acid alteration at position 192 of VP1 confers resist‐
ance to BPR0Z-194 [108].
Pleconaril, an anti-viral produced by Sterling-Winthrop, Inc., USA incorporates itself into
the capsid of  enteroviruses and blocks the virus from docking to cellular  receptors  and
uncoating  to  release  RNA into  the  cell.  It  targets  VP1  and  has  already  passed  the  last
stage  of  clinical  trials  [109].  Results  are  promising with  pleconaril  showing antiviral  ef‐
fects for most enteroviruses [109, 110]. Presently, there is an ongoing study on the effica‐
cy  of  pleconaril  in  enteroviral  sepsis  syndrome  in  neonates  [111].  The  National  Health
Research Institutes (NHRI) in Taiwan has reported a number of virtual compounds with
similar  stable  conformations  and  preliminary  studies  have  identified  a  few  promising
imidazolidinone derivatives.
13. Potential treatments in the future – RNA interference
Another promising therapy is the use of RNA interference (RNA-i) in silencing viral gene
expression [28, 112]. As aforementioned, viruses penetrate the BBB and the very nature of
the BBB makes it difficult for large and charged molecules to cross it. RNA-i on the other
hand, are small and have the potential to cross the BBB and exert a therapeutic effect. RNA-i
can bind to specific viral mRNA, causing degradation and preventing the translation and
synthesis of viral proteins that enable the virus to inhibit the host IFN-1 response [112]. To
synthesize RNA-i for therapeutic use, the viral proteins and subsequent viral mRNA have to
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be identified in advance. In vitro experiments performed have shown effective inhibition of
EV71 infection [113] however in vivo experiments utilizing murine models have yet to repli‐
cate similar results [114].
14. Prognosis
There are cases where spontaneous recoveries do not occur and neurological symptoms per‐
sist. A retrospective study of 105 patients from 1966 to 1972, with documented enterovirus
infection and CNS complications, revealed that half, 9 out of 18, of the children not lost to
follow up still displayed signs after 1-5 years [78]. Magnetic resonance imaging of two cases
with neurological sequelae demonstrated hypointense lesions on T1-weighted images and
hyperintense lesions on T2-weighted images, implying tissue destruction [61]. In a more re‐
cent retrospective study of 177 cases with enterovirus isolated via throat swab or stool speci‐
men, 92 patients (52%) had nervous system involvement, out of which 13 patients (7%) had
persistent neurological deficits at discharge [19]. Out of the 92 patients with neurological in‐
volvement, 67 (73%) had EV71 isolated and of the 13 patients with deficits at discharge, 11
(85%) had EV71 isolated. The persistent neurological deficits ranged from dysphagia and
weakness to lack of regular, spontaneous respiration despite presence of brain function [19].
Studies have also linked EV71 CNS infections to increased symptoms of inattention, hyper‐
activity, oppositional defiance, internalizing problems, and greater likelihood of the diagno‐
sis of attention deficit hyperactivity disorder [115].
Overall, mortality rates for HFMD is reported to be at 0.05% in China [19]. In the aforemen‐
tioned retrospective study of 177 cases, 5 mortalities were reported and in all these 5 cases,
EV71 was isolated [19]. Of the 5 mortalities, 2 were attributed to neurogenic pulmonary ede‐
ma, 2 to shock and 1 to brain-death. Mortalities in EV71 infection is generally due to neuro‐
genic pulmonary edema secondary to medulla destruction [13, 80, 116, 117]. In Taiwan, the
Department of Health has recorded a decrease of incidence in recent years, however the
mortality rate is still high (9 deaths in 1999, 41 deaths in 2000, 58 deaths in 2001) [60].
15. Conclusion
The reemergence and emergence of viral infections with involvement of the neurological
system is a challenge to public health officers, clinicians and researchers. Enterovirus infec‐
tion is a major concern with changing circulating genotypes in Asia. While CNS complica‐
tions of encephalitis are being increasingly reported in enterovirus infections, further
research is needed to understand whether this is due to increased virulence or due to unde‐
tected immune system defects. The epidemiology continuously evolves with shifting popu‐
lation and hence, there is also a need to have better diagnostic methods and treatment
options.
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